Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2026-01-27 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2026 first extraordinary shareholders meeting of Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting date, attendance, voting results for board elections, and legal opinions on the meeting's validity. There is no financial data or report content, but rather the official voting results and meeting details. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3359 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation.
2026-01-27 Chinese
沃森生物：职工董事管理制度
Governance Information Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 职工董事管理制度' which translates to 'Yunnan Watson Biotechnology Co., Ltd. Employee Director Management System'. It details the rules, responsibilities, nomination, election, rights, obligations, term, and management of employee directors within the company. The content is about governance practices related to board members representing employees, including legal references and company bylaws. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, no capital changes, and no report publication announcements. The document is a governance-related internal policy document describing the structure and management of employee directors on the board. Therefore, it fits best under Governance Information (CGR). The document length is 3587 characters, which is not extremely short, and it is not an announcement but the actual policy text. Hence, the classification is CGR with high confidence.
2026-01-27 Chinese
关于聘任公司高级管理人员、董事会秘书和证券事务代表暨部分高级管理人员变动的公告
Board/Management Information Classification · 100% confidence The document is an announcement from a company regarding the appointment and changes in senior management positions, including the president, vice presidents, financial director, board secretary, and securities affairs representative. It details the approval process, qualifications, and compliance with relevant regulations. There is no financial data, earnings information, or report publication mentioned. The content clearly fits the category of Board/Management Information, as it concerns changes in the company's board and senior management.
2026-01-27 Chinese
关于董事会完成换届选举暨部分董事变更的公告
Board/Management Information Classification · 100% confidence The document is an announcement from a company about the completion of a board of directors election and changes in some directors. It details the election results, names of new directors, their qualifications, and the departure of a previous director. There is no financial data, earnings information, or report publication mentioned. The content focuses on board composition and management changes, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report or a certification, so it is not a regulatory filing or report publication announcement.
2026-01-27 Chinese
北京市竞天公诚律师事务所上海分所关于公司2026年第一次临时股东会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and results of the 2026 first extraordinary general meeting (临时股东会) of Yunnan Watson Biotechnology Co., Ltd. It details the legality of the meeting's call, attendance, voting procedures, and election results of the board of directors. The document does not contain financial statements or performance data but focuses on the legality and procedural correctness of the shareholder meeting and board elections. This type of document is a legal opinion related to a shareholder meeting, not the meeting materials themselves, nor the voting results announcement alone. It is not an annual or interim report, earnings release, or any financial report. It is also not a proxy solicitation or governance report. Given the nature of the document as a legal opinion on the shareholder meeting, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or compliance documents that do not fit other categories.
2026-01-27 Chinese
第六届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the first meeting of the sixth board of directors of Yunnan Walvax Biotechnology Co., Ltd. It includes election of the chairman, vice chairman, appointment of the president, board secretary, other senior management, and securities affairs representative. It also provides biographies of these individuals and confirms compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The content focuses on board and senior management changes and appointments. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 7420 characters, which is sufficient for a full announcement rather than a brief notice or report publication announcement.
2026-01-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.